Important information
For patients
The Consumer Medicine Information (CMI) provides clear, easy-to-understand information to consumers and their carer on what they need to know before, during and after taking their medicine. This CMI is specific to Australia and does not replace advice from a healthcare professional. If you have any questions or concerns about the CMI, please consult your doctor.
For healthcare professionals
The Product Information (PI) is designed to support healthcare professionals in making informed treatment decisions and offering guidance on the proper use of this product. This information is intended exclusively for use in Australia.
Patient information portal
This portal will help answer many of the questions commonly asked by people with Dravet syndrome who are taking FINTEPLA.
Neither the CMI, nor the PI, are intended to promote any prescription product to the public.
FINTEPLA® is a registered trademark of UCB Biopharma SRL.
AU-FA-2400057. May 2025.